Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

Abstract

ObjectivesWe developed a conceptual model to define key concepts associated with patients’ experiences with the signs, symptoms, and impacts of non-metastatic castration-resistant prostate cancer (M0-CRPC).MethodsA targeted review of peer-reviewed literature, and other publicly available information, identified and categorized symptoms and impacts related to early-stage prostate cancer. Semi-structured interviews with five clinical experts helped determine the most relevant and important concepts for patients with M0-CRPC. Qualitative interviews with 17 patients with M0-CRPC identified the most frequently experienced symptoms and impacts, and their degree of interference with patients’ lives. The findings from these three lines of evidence were summarized in a conceptual model.ResultsLiterature searches identified mainly urinary, intestinal, and sexual symptoms. Experts noted the symptoms most frequently mentioned by patients include erectile dysfunction, loss of sexual desire or interest, incontinence/leaking, urgency, and hot flashes. Patient interviews confirmed the high frequency of erectile dysfunction, loss of libido, urinary urgency, and incontinence. The most frequently mentioned impacts expressed by patients were the need to monitor/plan for urinary frequency, interference with/restriction of daily activities, and frustration or anxiety over diagnosis, symptoms, or treatment. Symptoms and impacts most frequently experienced by patients were typically not those with the greatest effects on their lives; rather, those with the greatest consequences were related to treatment.ConclusionsThe leading concerns associated with M0-CRPC were related to voiding and sexual dysfunction. The most relevant symptoms and impacts expressed by patients may be a consequence of therapy rather than of the disease.Electronic supplementary materialThe online version of this article (doi:10.1007/s40271-017-0227-y) contains supplementary material, which is available to authorized users.

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

“…In the ARAMIS trial of darolutamide plus ADT versus placebo plus ADT, treatment with darolutamide significantly delayed the time to worsening of prostate cancererelated HRQoL, as measured by the FACT-P PCS scores, thereby maintaining patients' QoL for a longer period than placebo. Urinary and bowel symptoms are the major contributing factors leading to deterioration of QoL in patients with nmCRPC [12,13]. The post hoc analysis of time to deterioration of EORTC a Patients were asked 12 questions (FACT-P PCS) with the exception of screening, day 1, week 16 and the end of treatment, when patients were asked 39 questions (FACT-P PCS was collected in combination with overall FACT-P).…”

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

“…Patients were self-screened electronically using a screener adapted from a prior study. 30 Eligibility was based on the following criteria: ≥18 years old, diagnosed with prostate cancer, had undergone surgical or medical castration, had rising PSA levels, and was not told by a physician that the prostate cancer had spread to any other part of his body. Caregivers were eligible if they were the primary caregiver of a patient who fulfilled the aforementioned criteria.…”

A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospect

“…In addition to these challenging aspects, there are other serious issues including toxicity burdens, severe treatment side effects like sexual dysfunction and high costing of the entire treatment procedure due to use of highly expensive treatment modalities [31][32][33][34]. For increasing efficacies and determining the optimal sequencing strategies among currently used therapeutics, there is an urgent need to get a comprehensive view over these resistance mechanisms in prostate cancer.…”